Harrow (HROW) Invested Capital (2011 - 2024)

Harrow (HROW) posted quarterly Invested Capital of $37.0 million for Q3 2024, up 246566.67% quarter-over-quarter from $15000.0 in Q1 2022.

Harrow (HROW) Invested Capital (2011 - 2024) Analysis & Trends

Harrow's Invested Capital history runs 11 years deep, the most recent figure standing at $37.0 million for Q3 2024.

In Q3 2024, Invested Capital changed N/A year-over-year to $37.0 million; the TTM figure through Jun 2025 stood at $37.0 million (changed N/A YoY), while the FY2021 annual figure was $18000.0, down 28.0% from the prior year.
Invested Capital for Q3 2024 stood at $37.0 million, up from $15000.0 in the prior quarter.
The five-year high for Invested Capital was $37.0 million in Q3 2024, with the low at $15000.0 in Q1 2022.
The 4-year median for Invested Capital is $24000.0 (2021), against an average of $4.1 million.
Peak annual rise in Invested Capital reached 19.35% in 2020, while the deepest fall reached 92.48% in 2020.
Harrow's Invested Capital stood at $25000.0 in 2020, then slipped by 28.0% to $18000.0 in 2021, then fell by 16.67% to $15000.0 in 2022, then soared by 246566.67% to $37.0 million in 2024.
Business Quant data shows HROW's Invested Capital at $37.0 million in Q3 2024, $15000.0 in Q1 2022, and $18000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	9.90 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	4.50 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	3.74 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	1.74 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	73.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	630.00 Mn
10	Harrow	1.56 Bn	1.47 Bn	50.36 Mn	-

Download Data